{"generic":"Human Papillomavirus Recombinant Vaccine Bivalent (Types 16, 18)","drugs":["Cervarix","Human Papillomavirus Recombinant Vaccine Bivalent (Types 16, 18)"],"mono":{"0":{"id":"jx7ss0","title":"Generic Names","mono":"Human Papillomavirus Recombinant Vaccine Bivalent (Types 16, 18)"},"1":{"id":"jx7ss1","title":"Dosing and Indications","sub":{"0":{"id":"jx7ss1b4","title":"Adult Dosing","mono":"<ul><li><b>Adenocarcinoma in situ of cervix; Prophylaxis:<\/b> (through 26 years and previously unvaccinated) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months<\/li><li><b>Adenocarcinoma in situ of cervix; Prophylaxis:<\/b> (through 25 years) 0.5 mL IM for 3 doses at 0, 1, and 6 months<\/li><li><b>Cervical cancer; Prophylaxis:<\/b> (through 26 years and previously unvaccinated) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months<\/li><li><b>Cervical cancer; Prophylaxis:<\/b> (through 25 years) 0.5 mL IM for 3 doses at 0, 1, and 6 months<\/li><li><b>Cervical intraepithelial neoplasia, Grade 1, 2, 3; Prophylaxis:<\/b> (through 26 years and previously unvaccinated) 0.5 mL IM for 3 doses at 0, 1 to 2, and 6 months<\/li><li><b>Cervical intraepithelial neoplasia, Grade 1, 2, 3; Prophylaxis:<\/b> (through 25 years) 0.5 mL IM for 3 doses at 0, 1, and 6 months<\/li><\/ul>"},"1":{"id":"jx7ss1b5","title":"Pediatric Dosing","mono":"<ul><li><b>Adenocarcinoma in situ of cervix; Prophylaxis:<\/b> (9 years or older) 0.5 mL IM for 3 doses at 0, 1, and 6 months, or at 0, 1 to 2, and 6 months<\/li><li><b>Cervical cancer; Prophylaxis:<\/b> (9 years or older) 0.5 mL IM for 3 doses at 0, 1, and 6 months, or at 0, 1 to 2, and 6 months<\/li><li><b>Cervical intraepithelial neoplasia, Grade 1, 2, 3; Prophylaxis:<\/b> (9 years or older) 0.5 mL IM for 3 doses at 0, 1, and 6 months, or at 0, 1 to 2, and 6 months<\/li><\/ul>"},"3":{"id":"jx7ss1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Adenocarcinoma in situ of cervix; Prophylaxis<\/li><li>Cervical cancer; Prophylaxis<\/li><li>Cervical intraepithelial neoplasia, Grade 1, 2, 3; Prophylaxis<\/li><\/ul>"}}},"3":{"id":"jx7ss3","title":"Contraindications\/Warnings","sub":[{"id":"jx7ss3b9","title":"Contraindications","mono":"allergic reactions, severe (eg, anaphylaxis), to any component of the vaccine <br\/>"},{"id":"jx7ss3b10","title":"Precautions","mono":"<ul><li>acute illness with or without fever, moderate or severe; defer vaccination unless the benefit of protection outweighs the risk of an adverse reaction<\/li><li>latex sensitivity; tip cap and\/or rubber plunger of prefilled syringes contain dry natural latex rubber<\/li><li>pregnancy; not recommended; if pregnancy occurs after starting vaccination series, delay remainder of series until pregnancy complete<\/li><li>syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported; monitoring recommended<\/li><li>vaccine hypersensitivity; review immunization history and assess risks and benefits prior to administration<\/li><li>report suspected adverse events to GlaxoSmithKline at 1-888-825-5249 or to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or www.vaers.hhs.gov<\/li><\/ul>"},{"id":"jx7ss3b11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"jx7ss3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jx7ss5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (48.4%), Injection site pain (91.9%), Swelling at injection site (44.3%)<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal symptom (27.9%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (20.7%), Myalgia (48.8%)<\/li><li><b>Neurologic:<\/b>Headache (53.4%)<\/li><li><b>Other:<\/b>Fatigue (54.6%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Syncope<\/li><li><b>Dermatologic:<\/b>Erythema multiforme<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Other:<\/b>Angioedema<\/li><\/ul>"},"6":{"id":"jx7ss6","title":"Drug Name Info","sub":[{"id":"jx7ss6b17","title":"US Trade Names","mono":"Cervarix<br\/>"},{"id":"jx7ss6b18","title":"Synonyms","mono":"Human Papillomavirus Recomb Vaccine Bivalent<br\/>"},{"id":"jx7ss6b19","title":"Class","mono":"Vaccine<br\/>"},{"id":"jx7ss6b20","title":"Regulatory Status","mono":"RX<br\/>"}]},"7":{"id":"jx7ss7","title":"Mechanism Of Action","mono":"development of IgG neutralizing antibodies against HPV L1 capsid proteins generated as a result of vaccination <br\/>"},"9":{"id":"jx7ss9","title":"Administration","mono":"<b>Intramuscular<\/b><br\/><ul><li>shake vial or syringe well before use<\/li><li>administer IM in the deltoid region of upper arm; do not administer IV, subQ, or intradermally<\/li><\/ul>"},"10":{"id":"jx7ss10","title":"Monitoring","mono":"syncope, including tonic-clonic movements and other seizure-like activity; for 15 minutes after administration <br\/>"},"13":{"id":"jx7ss13","title":"Clinical Teaching","mono":"<ul><li>Warn patient that the tip cap and plunger of the need&le;ss prefilled syringes contain dry natural latex rubber that may cause allergic reaction in patients with latex sensitivity.<\/li><li>Advise patient that vaccine does not actually treat cervical cancer or other diseases that are caused by human papillomavirus.<\/li><li>Drug may cause fatigue, headache, myalgia, arthralgia, gastrointestinal symptoms, and pain, redness, and swelling at the injection site.<\/li><li>Inform patient that drug is given in 3 doses at 0, 1, and 6 months.<\/li><\/ul>"}}}